Trials / Completed
CompletedNCT00235885
Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)
Safety and Efficacy of Adalimumab in Patients With Active Psoriatic Arthritis (PsA) - An Open-Label, Multinational Study to Evaluate the Response to Every-Other Week Adalimumab When Added to Insufficient Standard Therapy, Including Patients Who Failed Prior Treatment With Other TNF-Inhibitors (STEREO)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 445 (planned)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the safety and clinical efficacy of adalimumab in active psoriatic arthritis (PsA) subjects when adalimumab is added to insufficient standard therapy including patients that have failed other TNF therapies
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | adalimumab |
Timeline
- Start date
- 2005-07-01
- First posted
- 2005-10-12
- Last updated
- 2007-08-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00235885. Inclusion in this directory is not an endorsement.